Compound ID | 351
HR 916B (Prodrug of RU29246)
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Description: | Pro-drug ester; bioavailability was increased from 5% in mice and rats to 80% with the prodrug; in phase I trials, bioavailability was higher than other 3rd generation Cephalosporins and was well tolerated; Mendes P, Meyer BH, Miiller F O, et al. Pharmacokinetics of cefdaloxime pentexil tosilate (HR 916 K) after a single oral dose in healthy volunteers. 32nd-ICAAC 1992;142. |
| Institute where first reported: | Hoechst Marion Roussel (Sanofi Aventis, France) |
| Year first mentioned: | 1991 |
| Highest development stage: | Phase 1 |
| Development status: | Inactive |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/substance/274181871 |
| Citation: | https://link.springer.com/article/10.1007/BF01961678 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.